Designing a First-in-Human Single-Ascending-Dose Study of a Once-Weekly Basal Insulin Analogue in Adults with Type 2 Diabetes: Dose Logic, Hypoglycemia Safeguards, and Phase 1 Protocol Synopsis
For a basal insulin engineered to act for a full week, the first human dose raises a problem that the usual first-in-human logic does not solve: a dose cannot be taken back, a glucose-lowering effect can persist for days, and a healthy volunteer has no hyperglycemia for the drug to treat. This article develops a hypothetical Phase 1 randomized single-ascending-dose study of a once-weekly acylated basal insulin analogue in adults with type 2 diabetes who already inject basal insulin, with an ultra-long-acting once-daily basal insulin as the active reference. It anchors four dose levels from 1.4 to 5.6 U/kg to the participants' own daily basal dose, with steps of 2.0-, 1.5-, and 1.33-fold, and it gates each cohort by sentinel dosing, a 72-hour observation, and a Safety Review Committee. The synopsis specifies 32 participants, 21 pharmacokinetic samples per participant to 42 days, continuous glucose monitoring, a graded hypoglycemia and rescue plan, and a descriptive statistical analysis. The article explains why a starting dose is tied to pharmacology instead of a toxicology no-effect level, and compares the design with healthy-volunteer and oncology first-in-human designs.Keywords: first-in-human; basal insulin analogue; once-weekly insulin; single ascending dose; hypoglycemia; continuous glucose monitoring; sentinel dosing; IND
Authors
- Peivand Pirouzi
- Happy Makvana
- Drashti Patel
- Sahil Patel
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426460
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00